This study is for people with a type of lung cancer called non-small cell lung cancer (NSCLC). The researchers want to find out if a new drug combination works better than the current treatment. They are looking at a drug called sacituzumab tirumotecan combined with another drug called pembrolizumab, comparing it to using pembrolizumab alone. The main goal is to see which treatment helps people live longer.

Not everyone can join this study. You need to have a confirmed diagnosis of NSCLC with a certain protein called PD-L1 present in at least 50% of your tumor cells. You should not have had certain treatments before, and there are other health conditions that might prevent you from joining.

• Study Length: You may receive treatment in up to 9 cycles if your disease progresses after the first course.
• Visits Needed: Regular visits are required for treatment and check-ups.
• Risks: Possible drug reactions and side effects; discuss with your doctor.

If you meet all the requirements and are interested, talk to your doctor about joining this study.